Supernus Pharmaceuticals, Inc. (SUPN) DCF Valuation

Supernus Pharmaceuticals, Inc. (SUPN) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Supernus Pharmaceuticals, Inc. (SUPN) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain mastery over your Supernus Pharmaceuticals, Inc. (SUPN) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real (SUPN) data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Supernus Pharmaceuticals, Inc.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 392.8 520.4 579.8 667.2 607.5 683.5 769.0 865.3 973.5 1,095.3
Revenue Growth, % 0 32.5 11.41 15.09 -8.95 12.51 12.51 12.51 12.51 12.51
EBITDA 180.4 212.4 129.2 153.4 90.0 200.8 225.9 254.1 285.9 321.7
EBITDA, % 45.94 40.82 22.28 23 14.82 29.37 29.37 29.37 29.37 29.37
Depreciation 10.2 20.0 32.6 85.6 84.9 53.1 59.8 67.3 75.7 85.1
Depreciation, % 2.6 3.84 5.62 12.83 13.97 7.77 7.77 7.77 7.77 7.77
EBIT 170.2 192.4 96.6 67.8 5.2 147.6 166.1 186.9 210.2 236.6
EBIT, % 43.33 36.97 16.66 10.16 0.8533 21.6 21.6 21.6 21.6 21.6
Total Cash 347.1 422.5 339.7 461.3 254.9 463.8 521.8 587.1 660.5 743.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 87.3 140.9 148.9 165.5 144.2
Account Receivables, % 22.24 27.07 25.69 24.8 23.73
Inventories 26.6 48.3 86.0 91.5 77.4 78.4 88.2 99.3 111.7 125.6
Inventories, % 6.78 9.29 14.83 13.72 12.74 11.47 11.47 11.47 11.47 11.47
Accounts Payable 10.1 6.1 9.3 10.5 2.0 9.9 11.2 12.6 14.2 15.9
Accounts Payable, % 2.58 1.18 1.61 1.58 0.32328 1.46 1.46 1.46 1.46 1.46
Capital Expenditure -2.7 -3.4 -2.0 -.4 -.6 -2.5 -2.9 -3.2 -3.6 -4.1
Capital Expenditure, % -0.69662 -0.66276 -0.35272 -0.06174708 -0.09069645 -0.37291 -0.37291 -0.37291 -0.37291 -0.37291
Tax Rate, % 52.47 52.47 52.47 52.47 52.47 52.47 52.47 52.47 52.47 52.47
EBITAT 130.5 144.8 70.5 67.8 2.5 110.0 123.7 139.2 156.6 176.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 34.1 82.1 58.6 132.1 113.7 142.8 150.9 169.8 191.1 215.0
WACC, % 8.46 8.46 8.45 8.48 8.42 8.45 8.45 8.45 8.45 8.45
PV UFCF
SUM PV UFCF 674.5
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 224
Terminal Value 5,019
Present Terminal Value 3,345
Enterprise Value 4,019
Net Debt -34
Equity Value 4,053
Diluted Shares Outstanding, MM 56
Equity Value Per Share 73.01

What You Will Get

  • Pre-Filled Financial Model: Supernus Pharmaceuticals' actual data facilitates accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Automatic updates provide immediate results as you adjust inputs.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, allowing for repeated use in comprehensive forecasts.

Key Features

  • Comprehensive SUPN Data: Pre-filled with Supernus Pharmaceuticals’ historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Develop multiple forecast scenarios to evaluate various valuation outcomes.
  • User-Friendly Design: Intuitive, organized, and suitable for both professionals and novices.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Supernus Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Supernus Pharmaceuticals’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Supernus Pharmaceuticals, Inc. (SUPN)?

  • Accurate Data: Real Supernus financials provide dependable valuation outcomes.
  • Customizable: Tailor key inputs such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you from building from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use Supernus Pharmaceuticals, Inc. (SUPN)?

  • Investors: Gain insights into pharmaceutical investments with detailed market analysis.
  • Healthcare Analysts: Utilize comprehensive data to evaluate drug performance and market potential.
  • Consultants: Tailor reports and presentations using Supernus' strategic insights for client needs.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market trends with real-life case studies.
  • Educators and Students: Leverage this information as a resource for learning about the pharmaceutical industry.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Supernus Pharmaceuticals, Inc. (SUPN).
  • Real-World Data: Supernus’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns providing deeper insights into the company's performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Supernus Pharmaceuticals, Inc. (SUPN).
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results to aid decision-making.

No products were found matching.